Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension

Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by formation of chronic, organized thrombus in pulmonary arteries resulting in development of pulmonary hypertension. We describe the favorable recovery of a patient with inoperable CTEPH treated with combination riociguat and in...

Full description

Bibliographic Details
Main Authors:	John W. Swisher, PhD, MD, Dillon Elliott, PharmD, BCPS, BCCCP
Format:	Article
Language:	English
Published:	Elsevier 2017-01-01
Series:	Respiratory Medicine Case Reports
Subjects:	Riociguat Inhaled treprostinil Chronic thromboembolic pulmonary hypertension Nitric oxide Cyclic GMP Prostacyclin
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213007116301216

Similar Items

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
by: Nicholas S. Hill, et al.
Published: (2022-07-01)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
by: Julia McSweeney, et al.
Published: (2023-04-01)

Intravenous Treprostinil in Severe Inoperable Chronic Thromboembolic Pulmonary Hypertension Using Implantable Pumps—Single-Center Experience over More Than a Decade
by: Regina Steringer-Mascherbauer, et al.
Published: (2023-07-01)

Treatment Strategy Options in Inoperable Chronic Thromboembolic Pulmonary Hypertension Patients
by: N. V. Marukyan, et al.
Published: (2021-05-01)

The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil
by: Pavel Jansa, et al.
Published: (2023-07-01)

Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder
by: Helena Gauani, et al.
Published: (2023-03-01)

Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension
by: Adam J. Plaunt, et al.
Published: (2021-01-01)

Evaluation and Selection of the Inhaler Device for Treprostinil Palmitil Inhalation Powder
by: Helena Gauani, et al.
Published: (2022-04-01)

Unexpected Acceleration in Treprostinil Delivery Administered by a Lenus Pro® Implantable Pump in Two Patients Treated for Pulmonary Arterial Hypertension
by: Garance Kopp, et al.
Published: (2020-10-01)

BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension
by: Leslie A. Spikes, et al.
Published: (2022-04-01)

Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review
by: Abdullah A. Alqarni, et al.
Published: (2023-08-01)

Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing
by: Shelsey W. Johnson, et al.
Published: (2022-07-01)

Kv7 Channels in Cyclic-Nucleotide Dependent Relaxation of Rat Intra-Pulmonary Artery
by: Mohammed Al-Chawishly, et al.
Published: (2022-03-01)

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
by: Jenna M. Faircloth, et al.
Published: (2023-08-01)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
by: Jenna M. Faircloth, et al.
Published: (2023-03-01)

Inhaled prostacyclin for Eisenmenger syndrome complicated with miliary tuberculosis
by: Eva M. Marwali, et al.
Published: (2011-08-01)

Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension
by: Masataka Kuwana, et al.
Published: (2023-01-01)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
by: Vallerie V. McLaughlin, et al.
Published: (2017-12-01)

Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection
by: Raj Parikh, et al.
Published: (2022-10-01)

Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension
by: Pugliese SC, et al.
Published: (2016-01-01)

Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences
by: Asger Andersen, et al.
Published: (2017-01-01)

Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
by: N. H. Kim
Published: (2010-03-01)

Real‐world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting
by: Vijay P. Balasubramanian, et al.
Published: (2022-01-01)

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil
by: John F. Kingrey, et al.
Published: (2023-07-01)

Inhaled Pulmonary Vasodilators for the Treatment of Right Ventricular Failure in Cardio-Thoracic Surgery: Is One Better than the Others?
by: Maria Benedetto, et al.
Published: (2024-01-01)

Inhaled iloprost is an effective alternative therapy for persistent pulmonary hypertension in newborns
by: Şükran Yıldırım
Published: (2023-07-01)

Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension
by: Jan C. Kamp, et al.
Published: (2021-05-01)

Design, Development, and Evaluation of Treprostinil Embedded Adhesive Transdermal Patch
by: Ibrahim Alissa, et al.
Published: (2023-04-01)

Inhaled Iloprost as a First-Line Therapy for Persistent Pulmonary Hypertension of the Newborn
by: Seung Hyun Kim, et al.
Published: (2019-11-01)

Soluble Guanylate Cyclase Stimulators for Chronic Thromboembolic Pulmonary Hypertension Patients Treatment: New Data
by: M. A. Simakova, et al.
Published: (2020-05-01)

Prenatal treprostinil reduces the pulmonary hypertension phenotype in the rat model of congenital diaphragmatic hernia
by: Felix Rafael De Bie, et al.
Published: (2022-07-01)

Comparison of treprostinil and oral sildenafil for the treatment of persistent pulmonary hypertension of the newborn: a retrospective cohort study
by: Enhuan Wei, et al.
Published: (2023-11-01)

The Evolving Management and Treatment Options for Patients with Pulmonary Hypertension: Current Evidence and Challenges
by: Swisher JW, et al.
Published: (2023-03-01)

Prenatal treprostinil improves pulmonary arteriolar hypermuscularization in the rabbit model of congenital diaphragmatic hernia
by: Felix R. De Bie, et al.
Published: (2024-01-01)

Treprostinil Reconstitutes Mitochondrial Organisation and Structure in Idiopathic Pulmonary Fibrosis Cells
by: Lei Fang, et al.
Published: (2023-07-01)

Advances in Balloon Pulmonary Angioplasty for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
by: GAO Luyang, et al.
Published: (2023-09-01)

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Chronic thromboembolic pulmonary hypertension
by: Eckhard Mayer, et al.
Published: (2014-01-01)

Treatment of patients with chronic thromboembolic pulmonary hypertension: focus on riociguat
by: Smith ZR, et al.
Published: (2016-06-01)

Features of clinical, functional and hemodynamics profile, medical treatment and prognosis evaluation in patients with inoperable chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension according to the Russian registry
by: I E Chazova, et al.
Published: (2019-09-01)

Venoarterial extracorporeal membrane oxygenation for vasoplegic shock after treprostinil refill of an implanted intravenous pump: a case report
by: Lucía Valencia, et al.
Published: (2024-01-01)